Select a Region North America

Expertise

Krista Tantakoun

Associate Manager, Value & Evidence

Expertise:

医療経済およびアウトカムリサーチ (HEOR)

As an Associate Manager on the Value & Evidence team at EVERSANA™, Krista contributes to evidence synthesis projects that support global HEOR initiatives.

Since joining the team in 2020, Krista has been involved in activities that address pharmaceutical and/or medical device-related research such as systematic and targeted literature reviews, feasibility assessments, indirect treatment comparisons, and real-world data analysis. She has experience developing high-quality deliverables including technical reports, manuscripts, and conference presentations. Her work has focused on several therapeutic areas in oncology (breast cancer, multiple myeloma, renal cell carcinoma, prostate cancer) and rare diseases.

Krista holds a MSc degree in International Health Technology Assessment and Reimbursement from the University of Sheffield. In addition, she holds a Graduate Diploma in Clinical Epidemiology from McMaster University and a BSc degree in Nutritional & Nutraceutical Sciences from the University of Guelph.

Articles by Krista Tantakoun

Cutting-edge Insights from EVERSANA's Global Value & Evidence Team
A Review of Indirect Treatment Comparisons (ITCs) in Regulatory Approval, Reimbursement and Pricing Recommendations for Oncology Drugs

The use of indirect treatment comparisons (ITCs) has increased significantly in recent years, particularly in the assessment of oncology and rare diseases where direct head-to-head trials may be impractical or unavailable, with numerous oncology and orphan drug submissions incorporating ITCs to support regulatory decisions and health technology assessment (HTA) recommendations. The Value & Evidence team at EVERSANA (Krista Tantakoun, Christopher Olsen, Fatemeh Mirzayeh Fashami, Imtiaz Samjoo and Chris Cameron), in collaboration with Dr. Brian Hutton, professors at Kyoto University and Yokohama City University School of Medicine in Japan, and colleagues at Janssen Pharmaceutical, critically reviewed and synthesized assessment documents for oncology drug submissions that included ITCs from various regulatory bodies […]

Cutting-edge Insights from EVERSANA's Global Value & Evidence Team
A Review of Worldwide Indirect Treatment Comparison (ITC) Guidelines and Best Practices

Considering the challenges of conducting head-to-head clinical trials, indirect treatment comparisons (ITCs) offer valuable insights into clinical effectiveness that reflect current and local practices. These insights can help regulators and reimbursement agencies make better-informed decisions, thereby facilitating patient access to novel treatments. Recent methodological advancements in ITCs have led to the release of regional, national and global guidelines outlining jurisdiction-specific methodology and reporting recommendations and/or best practices. The Value & Evidence team at EVERSANA (Krista Tantakoun, Christopher Olsen, Fatemeh Mirzayeh Fashami, Imtiaz Samjoo and Chris Cameron), in collaboration with Dr. Brian Hutton, professors at Kyoto University and Yokohama City University School of Medicine in Japan, and colleagues at Janssen Pharmaceutical, […]

Interested in scheduling a meeting or speaking event?

お問い合わせ